



OPEN ACCESS

EDITED BY

Melanie Grubisha,
University of Pittsburgh, United States

REVIEWED BY

Peter K. Giese,
King's College London,
United Kingdom
Kohji Fukunaga,
Tohoku University, Japan
Kim Dore,
University of California, San Diego,
United States

*CORRESPONDENCE

Hajime Fujii
hajime@m.u-tokyo.ac.jp
Haruhiko Bito
hbito@m.u-tokyo.ac.jp

†These authors have contributed
equally to this work and share first
authorship

SPECIALTY SECTION

This article was submitted to
Brain Disease Mechanisms,
a section of the journal
Frontiers in Molecular Neuroscience

RECEIVED 15 June 2022

ACCEPTED 25 July 2022

PUBLISHED 01 September 2022

CITATION

Fujii H, Kidokoro H, Kondo Y,
Kawaguchi M, Horigane S, Natsume J,
Takemoto-Kimura S and Bito H (2022)
Förster resonance energy
transfer-based kinase mutation
phenotyping reveals an aberrant
facilitation of
Ca²⁺/calmodulin-dependent CaMKII α
activity in *de novo* mutations related to
intellectual disability.
Front. Mol. Neurosci. 15:970031.
doi: 10.3389/fnmol.2022.970031

COPYRIGHT

© 2022 Fujii, Kidokoro, Kondo,
Kawaguchi, Horigane, Natsume,
Takemoto-Kimura and Bito. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which
does not comply with these terms.

Förster resonance energy transfer-based kinase mutation phenotyping reveals an aberrant facilitation of Ca²⁺/calmodulin-dependent CaMKII α activity in *de novo* mutations related to intellectual disability

Hajime Fujii^{1*}, Hiroyuki Kidokoro^{2†}, Yayoi Kondo¹,
Masahiro Kawaguchi², Shin-ichiro Horigane^{3,4},
Jun Natsume^{2,5}, Sayaka Takemoto-Kimura^{3,4} and
Haruhiko Bito^{1*}

¹Department of Neurochemistry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Department of Neuroscience I, Research Institute of Environmental Medicine (RIEM), Nagoya University, Nagoya, Japan, ⁴Department of Molecular/Cellular Neuroscience, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁵Department of Developmental Disability Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

CaMKII α plays a fundamental role in learning and memory and is a key determinant of synaptic plasticity. Its kinase activity is regulated by the binding of Ca²⁺/CaM and by autophosphorylation that operates in an activity-dependent manner. Though many mutations in CAMK2A were linked to a variety of neurological disorders, the multiplicity of its functional substrates renders the systematic molecular phenotyping challenging. In this study, we report a new case of CAMK2A P212L, a recurrent mutation, in a patient with an intellectual disability. To quantify the effect of this mutation, we developed a FRET-based kinase phenotyping strategy and measured aberrance in Ca²⁺/CaM-dependent activation dynamics *in vitro* and in synaptically connected neurons. CaMKII α P212L revealed a significantly facilitated Ca²⁺/CaM-dependent activation *in vitro*. Consistently, this mutant showed faster activation and more delayed inactivation in neurons. More prolonged kinase activation was also accompanied by a leftward shift in the CaMKII α input frequency tuning curve. In keeping with this, molecular phenotyping of other reported CAMK2A *de novo* mutations linked to intellectual disability revealed aberrant facilitation of Ca²⁺/CaM-dependent activation of CaMKII α in most cases. Finally, the pharmacological reversal of CAMK2A P212L phenotype in neurons was demonstrated using an FDA-approved NMDA receptor antagonist memantine, providing a basis for targeted therapeutics in CAMK2A-linked intellectual disability. Taken together,

FRET-based kinase mutation phenotyping sheds light on the biological impact of CAMK2A mutations and provides a selective, sensitive, quantitative, and scalable strategy for gaining novel insights into the molecular etiology of intellectual disability.

KEYWORDS

CaMKII, intellectual disability, neurodevelopmental disorders, imaging, FRET, *de novo* mutation

Introduction

Intellectual disabilities (ID) are prevalent in approximately 1% of the world population, and genetic as well as environmental factors play critical roles in ID pathogenesis (Vissers et al., 2016). Recently, *de novo* mutations in a key synaptic enzyme CAMK2A (Ca²⁺/calmodulin (CaM)- dependent protein kinase II alpha, CaMKII α) have been shown to be associated with ID (Küry et al., 2017; Akita et al., 2018). CaMKII α , which regulates synaptic plasticity, learning, and memory, is a protein kinase that is activated by Ca²⁺ transients caused by synaptic inputs or neuronal firing and modulates neuronal circuit properties *via* phosphorylation of key synaptic substrates leading to the up-regulation of AMPA-type glutamate receptor functions (Lisman et al., 1997, 2012; Woolfrey and Dell'Acqua, 2015; Takemoto-Kimura et al., 2017; Bayer and Schulman, 2019). Autoinhibitory domains self-inhibit their kinase activity under the baseline conditions, but are unblocked when Ca²⁺/CaM-binding is triggered, thus transforming neuronal activity into spatiotemporal domains of biochemical signaling (Bayer and Schulman, 2019). Upon autophosphorylation at threonine 286, an autonomous activity is achieved in which the kinase remains active even after the cessation of a Ca²⁺ rise (Hudmon and Schulman, 2002). Previously, it was determined that high-frequency neuronal stimuli facilitate this autonomy state in neurons (De Koninck and Schulman, 1998; Fujii et al., 2013). Frequency-tuning of CaMKII α integrates synaptic inputs during rapid learning and is thought to underlie the multifaceted roles of CaMKII α in learning and memory (Bayer and Schulman, 2019; Fujii and Bito, 2022).

Relatively small disturbances in CaMKII α expression cause significant brain dysfunction. Consistently, previous biochemical studies examining threonine 286 autophosphorylation in various ID-related *de novo* CAMK2A mutations suggested that some mutants were indeed upregulated, while others were downregulated (Küry et al., 2017; Akita et al., 2018). However, whether these mutations affected the key molecular phenotype, namely Ca²⁺/CaM-dependent activation and frequency-tuning, of CaMKII α have not been tested.

With a view to achieving a mechanistic understanding of ID and to begin to identify novel disease-modifying

therapeutic strategies, in this study, we developed a quantitative molecular phenotyping pipeline of ID-related *de novo* CAMK2A mutations. First, we identified an ID patient with a *de novo* CAMK2A Pro212Leu (P212L) mutation. In keeping with three previously identified cases, our patient with P212L mutation had a mild clinical phenotype, showing moderate ID and autistic features, but no dysmorphic features and no seizure events. Previous *in vitro* studies, however, have failed to identify any dysregulation of CaMKII α molecular phenotype as the heterologous expression of P212L mutant protein showed no change in protein expression or threonine 286 autophosphorylation levels (Küry et al., 2017).

To overcome this lack in molecular resolution, we built an analysis pipeline to quantitate the Ca²⁺/CaM-dependent activation of CaMKII α and uncover possible alteration in its frequency-tuning in neurons. We developed a Förster resonance energy transfer (FRET)-based optical molecular phenotyping system, in which we combined an optical CaMKII α FRET sensor hK2 α with multiple wavelength optical interrogation devices to analyze Ca²⁺/CaM-dependent activation in CaMKII α mutants related to ID.

Materials and methods

The studies involving human participants were reviewed and approved by the Ethics Committee of the Nagoya University Graduate School of Medicine. Written informed consent to participate in this study was provided by the participants' parents. All recombinant DNA and animal experiments in this study were performed in accordance with the regulations and guidelines for the care and use of experimental animals at the University of Tokyo and approved by the institutional review committees of the University of Tokyo Graduate School of Medicine.

Whole-exome sequencing

Genomic DNA was extracted from peripheral blood mononuclear cells using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Trio-WES (patient, father, and

mother) for the patient was performed using the Sure Select Human All Exon V6 kit for capture (Agilent Technologies, Santa Clara, CA, USA) and a HiSeq2500 system (Illumina, Inc., San Diego, CA, USA) for sequencing 101-bp paired-end reads. Obtained reads were aligned to the hg19 reference genome using the Burrows–Wheeler aligner (BWA, <http://bio-bwa.sourceforge.net/>) with default parameters and a *-mem* option. Polymerase chain reaction duplicates were removed using Picard tools (<http://broadinstitute.github.io/picard/>). Sequence variations were detected and annotated using VarScan2 (Koboldt et al., 2012) and ANNOVA R (Wang et al., 2010), respectively. For germline variations, we removed common single-nucleotide polymorphisms (SNPs) (defined as those with >1% allele frequency) using ExAC (<http://exac.broadinstitute.org/>), gnomAD (<https://gnomad.broadinstitute.org/>), 1,000 genomes (<http://www.1000genomes.org/>), ESP6500 (<http://evs.gs.washington.edu/EVS/>), and an in-house database. A conclusive assessment of molecular variants was performed according to guidelines issued by the American College of Medical Genetics and Genomics (ACMG) (Richards et al., 2015).

Sanger sequencing of *de novo* mutation

After genome extraction, the fragment from *CAMK2A* (NG_047040.1), including the mutation site, was amplified using PrimeSTAR GXL DNA polymerase (Takara) with primers, 5'-GGTTTGCAGGGACTCCTG-3' (forward) and 5'-CTGGTCAGTCTTCATGCTC-3' (reverse). Sanger sequencing was performed using the PCR fragments with the same forward primer.

Plasmid construction

The human *CAMK2A* clone (NM_171825.2) was purchased from GenScript. To construct humanized CaMKII α FRET probe hK2 α , a fragment containing kinase, regulatory and variable linker domain of CaMKII α , mVenus, and a fragment containing variable domain to association domain of CaMKII α were amplified by PCR using 5'-GGACTCAGATCTCGA GCCAGGATGGCCACCATCACCTGC-3' and 5'-CTTCAC ACCATCGCTCTT-3', 5'-AGCGATGGTGTGAAGGGTGG CGTGAGCAAGGGCGAGGAG-3' and 5'-GCTCTCTG AGGATTCGCCACCCTTGTACAGCTCGTCCAT-3', and 5'-GAATCCTCAGAGAGCACC-3' and 5'-TAGATCCGGTGGA TCCTCAGTGGGGCAGGACGGAGGG-3', respectively. The three fragments were assembled between XhoI and BamHI sites of pmCerulean-C1 to give pN1-hK2 α . The hK2 α containing *de novo* mutations was generated by quick change cite-directed mutagenesis methods. Forward and reverse primers used for each mutants were F98S: 5'-GGTGGGGA ACTGTCTGAAGATATCGTG-3' and 5'-CACGATATCTTCA

GACAGTTCCCCACC-3'; E109D: 5'-GAGTATTACAGT GACGCGGATGCCAGT-3' and 5'-ACTGGCATCCGCG TCACTGTAATACTC-3'; A112V: 5'-AGTGAGGCGGATG TCAGTCACTGTATC-3' and 5'-GATACAGTGACTGACAT CCGCCTCACT-3'; E183V: 5'-TATCTCTCCCCAGTAGT GCTGCGGAAG-3' and 5'-CTTCCGCAGCACTACTGGGG AGAGATA-3'; P212L: 5'-GTTGGGTACCCCCTGTCTG GGATGAG-3' and 5'-CTCATCCCAGAACAGGGGGTAC CCAAC-3'; P212Q: 5'-GTTGGGTACCCCAGTTCTGG GATGAG-3' and 5'-CTCATCCCAGAACTGGGGGTAC CCAAC-3'; P235L: 5'-GATTTCCCATCGCTGGAATGGGAC ACT-3' and 5'-AGTGTCCCATCCAGCGATGGGAAATC-3'; H282R: 5'-GCATCCTGCATGCGCAGACAGGAGACC-3' and 5'-GGTCTCCTGTCTGCGCATGCAGGATGC-3'; T286P: 5'-CACAGACAGGAGCCCGTGGACTGCCTG-3'; and 5'-CA GGCAGTCCACGGGCTCCTGTCTGTG-3'. Sequences of PCR-amplified region were confirmed by Sanger sequencing service (FASMAC, Japan). For the expression of cultured neurons, hK2 α was subcloned under the CaMKII promoter to obtain pCaMKII-hK2 α .

In vitro fluorescent plate reader

For FRET measurement in cell lysate, HEK293T cells (CRL11268, ATCC) were cultured in Dulbecco's Modified Eagle's Medium (D5796, Sigma-Aldrich) supplemented with fetal bovine serum and penicillin-streptomycin in 6-well-plates (IWAKI) and transfected with probe plasmids using XtremeGENE 9 (6365809001, Merck). Two to three days after transfection, cell lysates were collected with buffer containing 40 mM HEPES-Na, pH 8.0, 0.1 mM EGTA, 5 mM magnesium acetate, 0.01% Tween 20, sonicated using a sonicator (MICROSON ULTRASONIC CELL DISRUPTOR, XL2000-600, Misonix), and then centrifuged (TOMY, MX-300) to collect the supernatant. The protein concentration of the supernatant was determined by the Pierce BCA Protein Assay Kit (23227, Thermo Fisher Scientific) according to the manufacturer's protocol using the dilution series of pierce bovine serum albumin standard ampules, 2 mg/mL as the standard. The absorbance at 570 nm was quantified in a plate reader (IWAKI EZS-ABS Microplate Reader). To quantify the relative concentration of the probes in each sample, YFP fluorescence was measured by excitation at 510 nm and emission at 560 nm using a fluorescent plate reader (Infinite 200 PRO, Tecan).

In vitro FRET measurements were performed in 96-well-plates (PerkinElmer) and the probes were excited by 435 nm and measured by 485 nm for the CFP channel and were excited by 435 nm and measured by 535 nm for the YFP(FRET) channel, respectively. Lysate prepared from cells transfected with an empty vector was used for background subtraction. Total protein concentrations were adjusted to 70 or 80 μ g/ml using the empty vector lysate, and the relative fluorescent intensities

of each mutant sample were adjusted to give similar conditions between the mutants. As expression levels of E183V and P212Q were lower compared to other mutants, E183V, P212Q, and WT were compared in separate low expression groups, and other mutants (F98S, E109D, A112V, P212L, P235L, H282R, T286P) and WT were compared in the high expression group in Figure 5. For comparison of WT, P212L, and P212Q, the probe concentrations were adjusted to that of P212Q. Measurements were started at the volume of 99 μ l including the final 0.03 to 3 μ M of bovine calmodulin (Millipore or FUJIFILM Wako Chemicals) or a vehicle was added, and binding reactions were initiated by the addition of 2 μ l of 0.15 mM CaCl₂ (Nacalai Tesque, final 0.3 mM, 0.2 mM of free Ca²⁺ in the presence of 0.1 mM EGTA) and stopped by the addition of 2 μ l of 0.25 mM EGTA (Nacalai Tesque). For Ca²⁺/CaM vs. response plots, the mean FRET ratio of the last three points before the addition of EGTA was plotted against added CaM concentration.

Multiplex imaging of living neuron

Dissociated hippocampal neurons were prepared from the CA1/CA3 regions of the hippocampus of P0 Sprague–Dawley rat pups (Japan SLC) as described previously. At 9 days *in vitro*, neurons were co-transfected with plasmids encoding hK2 α and R-CaMP2 under CaMKII promoter using Lipofectamine 2000 (Thermo Fisher Scientific). After 4–6 days, the neurons were subjected to live cell imaging in Mg²⁺-free Tyrode's solution (129 mM NaCl, 5 mM KCl, 30 mM glucose, 25 mM HEPES-NaOH, pH 7.4, 2 mM CaCl₂; osmolality was adjusted to that of the conditioned culture medium using sucrose) supplemented with 0.5 mM MNI-glutamate (Tocris Bioscience) and 1 μ M TTX (Tocris Bioscience) to prevent contamination from spontaneous and recurrent activity. For the measurement of memantine dose-response curves, 1, 10, and 100 μ M memantine hydrochloride (Tokyo Chemical Industry) or vehicle (water) was added to the imaging solution. Neurons were maintained at around 37°C in a stage incubator (Tokai Hit) during all imaging sessions.

Neuronal cell bodies and dendritic spines were imaged using an inverted microscope (IX81, Olympus) equipped with an EM-CCD camera (C9100-13, Hamamatsu Photonics). UV photolysis of MNI-glutamate was performed with a 100x objective (UPlanSApo 100, NA 1.40, Olympus) and a 355-nm UV pulse laser (Polaris II, New Wave Research) that was controlled with a UV photolysis system (Hamamatsu Photonics) operated on an AQUACOSMOS software platform (Hamamatsu Photonics). Uncaging pulse rates were varied from 2.5 to 20 Hz with the use of a Master-8 pulse stimulator (A.M.P.I.). Excitation filters were FF01-438/24 (Semrock) for hK2 α excitation and ET555/20 \times (Chroma) for R-CaMP2 excitation, and each of the probes was sequentially excited with the use of filter exchanger OSP-EXA (Olympus) equipped with a mercury lamp (Olympus, USH-103OL). The emission filter was FF01-483/32

(Semrock) for the CFP channel and a combination of long-pass BA510IF (Olympus) and multiband band-pass fluorescence filter (FF01-433/517/613; Semrock) for YFP and R-CaMP2 channels. Camera exposure time was 10 ms for both hK2 α and R-CaMP2, and the data acquisition rate was about 25 Hz for neuronal soma imaging. For dendritic spine measurements, the exposure time was 100 ms and the acquisition rate was about 4 Hz. For comparison of baseline CFP/YFP ratio in the neuronal soma, neurons expressing hK2 α probes were live-imaged in normal Tyrode's solution (129 mM NaCl, 5 mM KCl, 30 mM glucose, 25 mM HEPES-NaOH, pH 7.4, 2 mM CaCl₂, 1 mM MgCl₂; osmolality was adjusted to that of the conditioned culture medium using sucrose) supplemented with 1 μ M TTX (Tocris Bioscience) using 10x objective (UPlanApo 10x, NA 0.40, Olympus), FF01-438/24 (Semrock) for excitation, FF01-483/32 (Semrock) for CFP emission, and FF01-542/27 (Semrock) for YFP emission. Data acquisition and ROI analysis were performed blindly in genotypes of hK2 α , except for memantine pharmacology experiments where about half of the data are acquired in open-label and the remaining half of the data were collected in blind in genotypes, drugs, and concentrations. Since the results from open- and blind-label experiments were similar, data from the open and blind labels were pooled and analyzed together in memantine pharmacology in Figure 8. For kinetics comparison in Figure 3, a neuron expressing WT hK2 α that showed little R-CaMP2 signal was excluded from the analysis, and CFP fluorescence intensities during the baseline period measured under the same acquisition conditions were not significantly different between WT and P212L (8,163 \pm 857 for WT, n = 19, 6913 \pm 566 for P212L, n = 19, p = 0.23, unpaired *t*-test), suggesting the expression levels of the measured cells were similar. For comparison of 9 mutants and WT in Figure 7, a total of 16 neurons was measured in response to 5 and 20 Hz stimulations for each mutant in a blind manner, and R-CaMP2 responses were manually checked before the opening of the labels, and those cells that showed little R-CaMP2 responses at 20 Hz (one WT, one E183V, and two H282R cells), unstable baseline (one E183V cell), or experimental human error (one T286P cell) were excluded from the analysis. Quantitative analysis of images was performed using AQUACOSMOS (Hamamatsu photonics). ROI was made in the cell body, and the cell-free area of the acquired images and the CFP, YFP, and RFP fluorescence intensities were measured at each time point. After background subtraction, the data at the time of uncaging light was contaminated, which was detected by thresholding, removed, and interpolated by linear interpolation of the previous and following frames. The rolling average was performed on the average of 5 consecutive time points.

The FRET signal was calculated by taking the CFP/YFP ratio as R and the increment ΔR ($=R-R_0$) from the pre-stimulus mean R_0 was normalized by R_0 , giving a normalized FRET ratio $\Delta R/R_0$. The R-CaMP2 signal was normalized by the pre-stimulus mean fluorescence F_0 , and the difference ΔF

from F_0 was divided by F_0 , giving a normalized fluorescence change $\Delta F/F_0$. To compare kinetics, the maximum value of $\Delta R/R_0$ or $\Delta F/F_0$ during a period of about 20 s after stimulus onset was detected and defined as peak $\Delta R/R_0$ and peak $\Delta F/F_0$, respectively. To compare the activation kinetics, half rise time, which is the time to reach half the magnitude of peak amplitude, was calculated. Specifically, half rise time point was defined as the time from the stimulus onset to the midpoint between the first time point when the response trace exceeded half of the peak amplitude and the last time point when the response trace was under half of the peak amplitude, during the time period from stimulus onset until the peak amplitude was reached. Next, to compare the inactivation kinetics, half decay time, which is the time from peak to decay to half the peak amplitude, was calculated. Specifically, half decay time was defined as the time from the peak to the midpoint between the first time point when the response trace decayed to half of the peak amplitude and the last time point that the response trace was above half of the peak amplitude. $\Delta F/F_0$ images of hK2 α and fluorescent images of R-CaMP2 in neurons were generated using Fiji. For neuronal soma, 10 average images were generated by excluding image frames containing artifacts due to uncaging, and ratiometric images were generated. The ratiometric images were normalized by dividing by the pre-stimulus R_0 images. For localization analysis in dendritic spines, mean YFP fluorescence intensities of hK2 α and mean R-CaMP2 fluorescence intensities during baseline periods before application of stimulations were used as proxies for the amount of hK2 α and volume, respectively. Spine enrichment index was defined as (hK2 α in spine / R-CaMP2 in spine) / (hK2 α in adjacent shaft / R-CaMP2 in adjacent shaft). For hK2 α and R-CaMP2 response measurements, those spines that showed a large decrease in FRET probe fluorescence (detected if CFP fluorescence was <85% of baseline or YFP fluorescence was less than 85% and CFP fluorescence was less than 90% of baseline after stimulation) or dim baseline fluorescence of R-CaMP2 (detected if baseline R-CaMP2 fluorescence intensities were less than twice of their standard deviations during the baseline period) were excluded from the analysis (WT had 17 decreased and 5 dim R-CaMP2 spines, P212L had 13 decreased and 2 dim R-CaMP2 spines excluded. Remaining 41 and 51 spines from 18 and 19 neurons were analyzed for WT and P212L, respectively). Peak amplitude was defined as the maximum of hK2 α and R-CaMP2 during 5 frames from the end of stimulation. To create hK2 α response images for 10 s before, immediately after, and 20 s after stimulation, CFP and YFP images were Gaussian-filtered [σ (radius) = 1 in ImageJ], and CFP/YFP ratio images were created. It was then divided by the pre-stimulus average ratio image and thresholded with a cellular mask to create $\Delta R/R_0$ images. A total of 3 frames of $\Delta R/R_0$ images were averaged and displayed. Similarly, for R-CaMP2 images, 3 frames of $\Delta F/F_0$ images were averaged and displayed. Statistical analysis was performed using Excel (Microsoft), BellCurve for Excel (Social

Survey Research Information Co., Ltd.), and EZR (Kanda, 2013) (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R.

Results

Identification of *de novo* P212L mutation in CAMK2A from a patient with ID and ASD


An 18-month-old Japanese girl presented to our clinic because she was unable to walk independently. She was the first child born to healthy non-consanguineous parents. She was born at the gestational age of 40 weeks with a birth weight of 3,550 g (+1.42 SD) and a birth head circumference of 34.0 cm (+0.35 SD). The family history is unremarkable. She was able to sit after age 7 months, creep after 10 months of age, and was able to stand with support at 15 months of age. She was able to speak some meaningful words.

Initial physiological and neurological examinations at 18 months of age revealed no abnormalities except for mild hypotonia. No distinctive facial features were observed. Screening blood tests, including metabolic and karyotyping, were normal.

At age 2 years, she was able to walk independently, but her speech development was delayed. Her total score on the Modified Checklist for Autism in Toddlers (M-CHAT) was 3, indicating that she was at risk for autism spectrum disorder (ASD). Brain MRI at age 2 years was normal. At age 3 years, she was able to run and speak three-word sentences. At age 4 years, inattention behavior and difficulty in controlling affection were present. At age 5 years, her parents noted difficulty with reading and writing, including the inability to read numbers, and she was asking the same questions. She was diagnosed with moderate ID as well as ASD, attention-deficit/hyperactivity disorder (ADHD), and developmental coordination disorder, according to the Tanaka-Binet test (Tanaka, 1987) and clinical interview of the Diagnostic Interview for Social and Communication Disorders (DISCO) (Wing et al., 2002).

After obtaining written informed consent for genetic testing and publication of identifying information/images in an online open-access publication, trio-based whole exome sequencing identified a *de novo* heterozygous missense variant (NM_015981: c.635C>T; p.Pro212Leu) in CAMK2A, which was subsequently confirmed by Sanger sequencing (Figure 1A). This variant is not listed in public SNP databases, including ExAC (<http://exac.broadinstitute.org/>) and the Human Genetic Variation Database (<http://www.hgvd.genome.med.kyoto-u.ac.jp/>). The same variant is reported to be a pathogenic variant, which leads to an ID (Küry et al., 2017).

At age 5 years, a follow-up brain MRI showed no structural or volumetric abnormalities, including



in the amygdalae and hippocampi (Figure 1B). Electroencephalography was normal. She had no other comorbidities such as epilepsy, infectious diseases, and visual and hearing impairments.


Development of FRET-based optical molecular phenotyping system for mutational analysis of CAMK2A

P212L mutation in a patient is the fourth report after three cases that have been reported (Küry et al., 2017), and thus it has been considered to be a recurrent *de novo* mutation in neurodevelopmental disorders. In addition, in the paralogous isoform CAMK2B, P213L mutation, which is in the same position as P212L in CAMK2A, has been found in a patient with neurodevelopmental disorders (Akita et al., 2018; Mutoh et al., 2022). These lines of clinical data strongly suggest the possibility that CAMK2A P212L mutation could alter the biochemical properties of CaMKII α that underlie neurodevelopmental disorders. However, previous attempts had failed to reveal how P212L mutation affects biochemical properties of CaMKII α , since protein expression levels and autophosphorylation level of threonine286 of P212L mutant under baseline conditions in heterologous cells or the migration of neuronal cells expressed with P212L mutant during cortical development were similar to those of WT (Küry et al., 2017). Although Ca²⁺/CaM-dependent activation is one of

the most fundamental properties of CaMKII α (Hudmon and Schulman, 2002; Lisman et al., 2012; Bayer and Schulman, 2019), previous studies had not examined how P212L mutation affects Ca²⁺/CaM-dependent activation, partly because of the lack of a sensitive, selective, quantitative, and scalable method to measure CaMKII α activation. To meet these requirements, we took advantage of the humanized version of K2 α , a FRET (Förster Resonance Energy Transfer)-based probe to monitor CaMKII α activation that we developed previously (Fujii et al., 2013). Previously, CaMKII α sensors that had one of the two fluorescent proteins attached to the C-terminus were developed (Takao et al., 2005; Lee et al., 2009), but to circumvent the potential folding problem (Shibata et al., 2015), K2 α incorporated it in the middle of the flexible variable linker region exposed to the external surface of the holoenzyme (Fujii et al., 2013; Myers et al., 2017). Its FRET changes reported Ca²⁺/CaM-dependent activation as well as the autophosphorylation to threonine 286 (Figure 2A) (Fujii et al., 2013), which is another hallmark of CaMKII α activation. Furthermore, its optical readout was shown to be quantitatively correlated with a conventional biochemical readout of CaMKII α activation, and it was able to perform quantitative pharmacological analysis using the FRET signal, providing a rationale for the quantification (Fujii et al., 2013). Therefore, we analyzed the effect of mutation by introducing a mutation into the hK2 α probe and comparing its signal change upon activation with WT hK2 α . We took two schemes for the mutational analysis, (1) plate reader FRET assay, in which quantitative Ca²⁺/CaM-dependent activation

curve of hK2 α was obtained using *in vitro* high-throughput fluorescent plate reader and (2) multiplexed imaging of live neuron co-expressed with hK2 α and red colorfast and linear

Ca²⁺ indicator R-CaMP2 (Inoue et al., 2015) in response to various patterns of local glutamate uncaging stimulations (Figure 2B).



P212L mutation aberrantly facilitated Ca²⁺/CaM-dependent CaMKII α activation and rendered the intracellular CaMKII α activation larger, faster and more sustained

For plate reader FRET assay, cell lysates prepared from HEK293T cells expressing hK2 α were mixed with CaM, and after measurement at baseline, Ca²⁺ was added to induce Ca²⁺/CaM-dependent activation. Both WT and P212L showed an increase in the CFP/YFP ratio (FRET ratio) upon the addition of Ca²⁺ (Figure 3A). Subsequent addition of EGTA lowered the increased FRET ratio (Figure 3A), confirming that FRET change represents Ca²⁺/CaM-dependent activation as in the previous study (Fujii et al., 2013). By changing the concentration of added CaM, CaM dose-response curves were obtained for WT and P212L (Figures 2A,B). P212L clearly showed enhanced Ca²⁺/CaM-dependent activation compared to WT under all the CaM concentrations examined (0, 0.03, 0.1, 0.3, 1, 3 μ M). Furthermore, P212L clearly showed activation under 0.03 μ M CaM, whereas WT activation occurred at 0.1 μ M or higher CaM concentrations, indicating facilitated Ca²⁺/CaM-dependent activation in P212L (Figures 3A,B).

In neurons, CaMKII α is activated by intracellular Ca²⁺ rises through NMDAR triggered by glutamate release, and it plays important roles in synaptic plasticity, learning, and neural development (Lisman et al., 2012), and the precise regulation of CaMKII α activity is required for normal brain functions (Fujii and Bito, 2022). As hK2 α P212L was activated at low concentrations of Ca²⁺/CaM, glutamate-input-dependent CaMKII α activation in neurons may be enhanced by P212L mutation. To investigate this possibility, hK2 α probes were transfected into hippocampal dissociated cultured neurons along with red Ca²⁺ indicator R-CaMP2 to check for Ca²⁺ rise induced by stimulation (Inoue et al., 2015). The cell bodies were stimulated by local glutamate uncaging in Mg²⁺-free solutions in the presence of TTX, which has been used to efficiently trigger NMDAR-mediated Ca²⁺ influx and CaMKII activation (Matsuzaki et al., 2004; Lee et al., 2009; Fujii et al., 2013), as we previously demonstrated that frequency-dependency of CaMKII α was observed in soma as well as in dendritic spines (Fujii et al., 2013). High-frequency stimulation (50 uncaging stimuli at 20 Hz), which efficiently triggers CaMKII α activation, resulted in a fast increase in the R-CaMP2 signal, followed by a slower increase in the hK2 α FRET signal (Figure 3C). The hK2 α signal persisted even after the R-CaMP2 signal returned to the baseline (Figures 3C,D,H), suggesting that CaMKII α keeps activated conformation by autonomous state and CaM trapping, consistent with the previous studies (Meyer et al., 1992; Hudmon and Schulman, 2002; Lisman et al., 2012; Fujii et al., 2013; Bayer and Schulman, 2019). Strikingly, P212L showed about \sim 60% larger peak amplitude of hK2 α compared to WT ($\Delta R/R_0$

of hK2 α : 0.28 ± 0.039 for WT, 0.44 ± 0.038 for P212L, $p < 0.01$, unpaired t -test) (Figure 3E). Furthermore, hK2 α activation was faster and more sustained in P212L compared to WT (Figure 3D). To quantitatively compare the kinetics, from the traces of each neuron, we calculated half-rise time, time from the start of stimulation to rise to half of the maximum amplitude, and the half-decay time, time from the peak to decay down to half of the maximum amplitude. These kinetics analyses demonstrated that P212L was activated about \sim 30% faster (half rise time: 1.9 ± 0.09 s for WT and 1.5 ± 0.09 s for P212L, $p < 0.01$, unpaired t -test) and sustained the activation about \sim 50% longer time (half decay time: 7.4 ± 0.64 s for WT and 11.0 ± 1.02 s for P212L, $p < 0.01$, unpaired t -test) (Figures 3F,G). There were no significant differences in peak amplitude, half rise time, and half decay time of R-CaMP2 signals ($\Delta F/F_0$ of R-CaMP2: 2.0 ± 0.11 for WT, 1.9 ± 0.09 for P212L, $p = 0.77$, unpaired t -test; half rise time: 0.81 ± 0.08 s for WT and 0.68 ± 0.05 s for P212L, $p = 0.13$, unpaired t -test; half decay time: 3.0 ± 0.4 s for WT and 3.4 ± 0.4 s for P212L, $p = 0.48$, unpaired t -test) (Figures 3H–K). CFP/YFP baseline ratio were not significantly different between WT and P212L (0.55 ± 0.012 for WT, 0.56 ± 0.012 for P212L, $p = 0.696$, unpaired t -test), suggesting comparable baseline activation levels. Thus, our multi-probe imaging and quantitative analysis revealed that P212L mutation resulted in greater, faster, and more sustained CaMKII α activation in the neurons.

Since biochemical reactions in the dendritic spine can be different from that of neuronal soma, considering the distribution of the molecules and small volumes (Kennedy et al., 2005), we compared hK2 α probe localization and response in the dendritic spine. To examine localization, we compared the relative enrichment of the hK2 α probe in the dendritic spine to the adjacent shaft using baseline fluorescence intensity R-CaMP2 before photo-stimulation as a proxy for volume marker (Figure 3L). hK2 α showed enrichment in the dendritic spine relative to the dendritic shaft, consistent with the previous reports (Otmakhov et al., 2004; Zhang et al., 2008), but there was no significant difference between WT and P212L (1.36 ± 0.032 for WT, 1.32 ± 0.031 for P212L, $p = 0.323$, unpaired t -test) (Figure 3M). Next, hK2 α and R-CaMP2 responses were measured against high-frequency uncaging stimuli (100 UV-uncaging stimuli delivered at 20 Hz) (Fujii et al., 2013). Consistent with the measurements in the neuronal soma, we observed that P212L showed larger responses in the stimulated dendritic spines ($\Delta R/R_0$ of hK2 α : 0.12 ± 0.032 for WT, 0.28 ± 0.026 for P212L, $p < 0.001$, Kolmogorov-Smirnov test, $p < 0.001$, unpaired t -test) (Figures 3O,P), while R-CaMP2 showed no significant difference ($\Delta F/F_0$ of R-CaMP2: 0.62 ± 0.05 for WT, 0.66 ± 0.046 for P212L, $p = 0.95$, Kolmogorov-Smirnov test, $p = 0.52$, unpaired t -test) (Figures 3Q,R). Together, our results clearly demonstrated that a P212L mutation caused a facilitated CaMK2 α activity, both in the soma and in the dendritic spines.




FIGURE 3 P212L mutation facilitated Ca^{2+} /CaM-dependent activation of CaMKII α , accelerates activation and decelerates inactivation processes. (A) Plate reader FRET measurement of WT (left) and P212L (right) mutant of hK2 α under various concentrations of added CaM. Ca^{2+} and EGTA are added (Continued)

FIGURE 3 (Continued)

as indicated by arrows. Concentrations of added CaM are coded by the darkness of the traces, as indicated at the right. Mean \pm s.e.m are shown ($n = 4$ for WT, $n = 4$ for P212L). **(B)** CaM concentration to FRET response plots for **(A)**. The mean of the last three points just before the addition of EGTA are plotted against CaM concentrations. Mean \pm s.e.m are shown ($n = 4$ for each). $*** p < 0.001$ for WT vs P212L, at each CaM concentration, Tukey *post-hoc* analysis followed by ANOVA. **(C)** Representative images for multi-probe live neuron imaging. FRET ratio images of WT hK2 α (top) and fluorescence images of R-CaMP2 (bottom) in response to local glutamate uncaging (50 photo-uncaging stimulations at 20 Hz) are shown. The time from the initiation of the stimulus sequence is indicated in seconds below in each image. **(D)** hK2 α response traces of WT (blue) and P212L (red) against glutamate uncaging (50 stimulations at 20 Hz). Mean \pm s.e.m are shown ($n = 19$ neurons for WT, $n = 19$ for P212L). **(E–G)** Comparison of hK2 α response peak $\Delta R/R_0$ **(E)**, activation half rise time **(F)**, deactivation half decay time **(G)** between WT (blue open square) and P212L (red filled circle). Each plot represents data from each individual neurons, and black bar represents the mean. $** p < 0.01$, unpaired *t*-test, $n = 19$ for WT $n = 19$ for P212L. **(H)** R-CaMP2 response traces in neurons co-transfected with hK2 α WT (blue) and hK2 α P212L (red) against glutamate uncaging (50 stimulations at 20 Hz). Mean \pm s.e.m are shown by line and shaded areas, respectively ($n = 19$ neurons for WT, $n = 19$ for P212L). **(I–K)** Comparison of R-CaMP2 response peak amplitude **(I)**, activation half rise time **(J)**, deactivation half decay time **(K)** between neurons co-transfected with hK2 α WT (blue open square) and hK2 α P212L (red filled circle). Each plot represents data from each individual neuron, and the black bar represents the mean. n.s., not significant, unpaired *t*-test ($n = 19$ neurons for WT, $n = 19$ for P212L). **(L,M)** Comparison of spine enrichment of hK2 α . **(L)** Representative images of hK2 α (left, green), baseline R-CaMP2 (middle, magenta), and their merged images for WT (top) and P212L (bottom). **(M)** Comparison of spine enrichment ($p = 0.323$, unpaired *t*-test, $n = 41$ spines, 18 neurons for WT, $n = 51$ spines, 19 neurons for P212L). **(N–R)** Comparison of responses in dendritic spines. **(N)** Representative images for hK2 α (top) and R-CaMP2 (bottom) responses ~ 10 seconds before the stimulation (left), immediately after the stimulation (middle), and ~ 20 seconds after the stimulation (right). **(O,P)** Cumulative distribution **(O)** and quantitative comparison **(P)** of hK2 α responses between WT and P212L ($p < 0.001$, Kolmogorov-Smirnov test, $p < 0.001$, unpaired *t*-test, $n = 41$ spines from 18 neurons for WT, $n = 51$ spines from 19 neurons for P212L). **(Q,R)** Cumulative distribution **(Q)** and quantitative comparison **(R)** of R-CaMP2 responses between WT and P212L ($p = 0.95$, Kolmogorov-Smirnov test, $p = 0.52$, unpaired *t*-test, $n = 41$ spines from 18 neurons for WT, $n = 51$ spines from 19 neurons for P212L).

Input frequency decoding properties of CaMKII α are tuned to lower frequencies in P212L mutant


Does the introduction of P212L only affect response amplitude and rise the decay kinetics of CaMKII α activation? Or is it possible that there is some effect on the information processing properties of neural inputs? It has been biochemically demonstrated that CaMKII α is activated depending on the frequency of Ca²⁺ pulses (De Koninck and Schulman, 1998) and accordingly, on the frequency of glutamate uncaging stimulation (Fujii et al., 2013). Such stimulus frequency-dependent activation of CaMKII α may play an important role in the regulation of the induction of input frequency-dependent plasticity as well as learning and memory (Bach et al., 1995; Mayford et al., 1995; Rotenberg et al., 1996; Chang et al., 2017; Bayer and Schulman, 2019; Fujii and Bito, 2022). Since CaMKII α activity sums up if the next input comes before the CaMKII α activation returns to the baseline (Hanson et al., 1994; Chang et al., 2017; Bayer and Schulman, 2019), slower deactivation kinetics in P212L could possibly alter input frequency tuning of CaMKII α . To investigate this possibility, glutamate uncaging stimulation was repeated 30 times at various frequencies (2.5, 5, 10, and 20 Hz), and multiplexed imaging of hK2 α and R-CaMP2 was performed (Figures 4A–D). Consistent with the previous studies (Fujii et al., 2013), WT showed little response up to 5 Hz, but the response increased at 10 and 20 Hz, and a frequency-dependent activation response was observed (Figures 4A,B). In contrast, P212L showed lowered frequency tuning (Figures 4A,B). Although little response was observed at 2.5 Hz, 5 Hz stimulus triggered a more pronounced response compared to WT (Figures 4A,B). hK2 α P212L reached nearly plateau level activation at 10 Hz (Figures 4A,B) (hK2 α amplitude

for WT and P212L: 2.5 Hz: 0.0061 ± 0.00082 , 0.024 ± 0.016 , $p = 0.63$; 5 Hz: 0.017 ± 0.0055 , 0.16 ± 0.037 , $p < 0.001$; 10 Hz 0.11 ± 0.025 , 0.32 ± 0.036 , $p < 0.001$; 20 Hz: 0.20 ± 0.029 , 0.35 ± 0.028 , $p < 0.001$; repeated measures ANOVA and Turkey's test, $n = 16$ for both WT and P212L). For R-CaMP2, significant dependency on the input frequency was observed in R-CaMP2 amplitude, but there was no difference between genotypes (repeated measures ANOVA, $p < 0.001$ for frequency, $p = 0.1411$ for genotype, $p = 0.1419$ for interaction). These results demonstrate that P212L mutation shifted the input tuning curve to a lower frequency and disrupted the information processing properties of the neurons.

Aberrantly facilitated Ca²⁺/CaM-dependent activation is a prevalent molecular phenotype among CAMK2A mutants related to ID

Is the facilitated Ca²⁺/CaM-dependent activation a molecular phenotype of CaMKII α solely observed in P212L? Or is it a phenotype that is also prevalent in other CAMK2A mutations found in ID? To answer this question, we took advantage of the high-throughput capability of our analytical pipeline and investigated a series of CAMK2A *de novo* mutations (F98S, E109D, A112V, E183V, P212L, P212Q, P235L, H282R, and T286P) identified from patients with ID (Küry et al., 2017; Akita et al., 2018).

In this analysis, to adjust for total protein concentration and probe concentration between the mutants being compared, 2 mutants (E183V and P212Q) that were particularly low in expression levels were compared to WT in one group, and 7



mutants (F98S, E109D, A112V, P212L, P235L, H282R, T286P) were analyzed in another group, although the WT response was almost identical between these conditions.

The results revealed three qualitatively different types. First, 6 mutants (F98S, E109D, P212L, P212Q, H282R, and T286P) showed a CaM dose-response curve similar to that of P212L and were more activated than WT, especially at low Ca²⁺/CaM concentrations (Figures 5A–C, F, G, I, J). Next, 2 mutants (A112V, P235L) showed Ca²⁺/CaM dose-response curves similar to WT (Figures 5A, D, H). The remaining one mutant (E183V) showed an elevated CFP/YFP ratio even in the basal state, and the modulation by Ca²⁺/CaM concentration was small (Figure 5E). These data demonstrate that facilitated CaM-dependent activation was not

P212L-specific but observed in 6 of the 9 CAMK2A *de novo* mutations related to ID.

Among the mutations analyzed, P212Q is a missense mutation that is altered at the same amino acid position as P212L. Although a small sample size precludes precise comparison, on comparing the current case with the reported case, the pathological phenotype of the patient with P212L reported here was milder compared to that of P212Q reported previously in terms of ID and the absence of seizures (Akita et al., 2018). Furthermore, autophosphorylation of threonine 286 was upregulated in P212Q, while P212L showed no significant difference (Küry et al., 2017; Akita et al., 2018). So, it can be predicted that facilitated Ca²⁺/CaM-dependent activation is more profound in P212Q compared to P212L. To elucidate if





FIGURE 5

FRET plate reader analysis of effects of *de novo* mutations identified from ID on Ca^{2+} /CaM-dependent activation of CaMKII α . (A–J) Plate reader FRET assay (left) and CaM dose response curves (right) for hK2 α WT and *de novo* mutants stimulated by 0, 0.03, 0.3, 3 μM added CaM. To ease comparison, dose-response curves of WT (shaded blue open square) are overlaid that of each mutant [red filled circle, (B–J)]. Mean \pm s.e.m. are indicated, two-way ANOVA followed by *post-hoc* Turkey's test ** p < 0.01, *** p < 0.001. n = 9 for WT, F98S, E109D, A112V, P212L, P235L, H282R and T286P and n = 14 for WT, E183V and P212Q.



there is a quantitative difference between P212L and P212Q, we directly compared P212L, P212Q, and WT by FRET plate reader assay. The results showed that P212Q was more readily activated than P212L at low concentrations of CaM (Figure 6).

Next, to elucidate the activation profiles of the *de novo* mutants of CaMKII α in living neurons, we performed multiplex imaging for a series of hK2 α mutants and measured their responses to 30 glutamate uncaging stimulations delivered at 5 or 20 Hz (Figures 7A–J, Supplementary Figures 1, 2).

Under these conditions, R-CaMP2 peak amplitudes for E109D, H282R, and T286P were significantly lower than WT for both 5- and 20-Hz stimuli (Supplementary Figures 1, 2). A112V and P235L showed a slight but significant decrease in R-CaMP2 response against 20-Hz stimuli compared with WT

(Supplementary Figure 2D). To best correct for the different Ca^{2+} levels between mutants, we took advantage of the fact that R-CaMP2 responds relatively linearly under a wide range of Ca^{2+} concentration (Inoue et al., 2015) and plotted hK2 α peak amplitude against R-CaMP2 peak amplitude (Figures 7K,L). By considering a line connecting the WT plot and the origin (baseline conditions), the responses of mutants plotted above this line are considered to be enhanced, while the responses of mutants plotted below it are considered to be attenuated (Figures 7K,L, blue dash lines). Consistent with the results from FRET plate reader assays, F98S, E109D, P212L, P212Q, H282R, and T286P were plotted above these lines, P235L was almost overlaid with these lines, and E183V was plotted below these lines. A112V was unexpectedly plotted under the line, and




FIGURE 7 Activation profiles of CAMK2A *de novo* mutations associated with ID in living neurons. (A–J) hK2 α activation traces in response to 30 photo-stimulations delivered at 5 Hz (left) or 20 Hz (right) To aid comparison, WT response traces (shaded blue traces) are overlaid in each mutant traces [red traces, (B–J)]. Mean \pm s.e.m. are shown. $n = 14$ for E183V and H282R, $n = 15$ for WT, E109D, and T286P, $n = 16$ for F98S, A112V, P212L, P212Q, and P235L. (K,L) R-CaMP2 peak amplitude vs. hK2 α peak amplitude plots. Mean \pm s.e.m. are shown.

the response was significantly lower than that of WT under 20 Hz stimulation, suggesting that processes other than Ca^{2+} /CaM-dependent activation could be impaired in neuronal conditions. Taken together, aberrantly facilitated Ca^{2+} /CaM-dependent CaMKII α activation was observed in two-thirds of ID-related *de novo* CAMK2A mutations reported so far, and is considered to be the prevalent molecular phenotype in ID.

Attenuation of NMDAR signaling normalized aberrant activation of P212L

Our data suggest that pharmaceutical intervention on CaMKII α activation is a reasonable candidate for ID caused by aberrantly facilitated Ca^{2+} /CaM-dependent CaMKII α activation. Since there is no approved CaMKII inhibitor for clinical use (Pellicena and Schulman, 2014; Nassal et al., 2020), we attempted to target upstream NMDAR-mediated Ca^{2+} influx using memantine, an NMDAR agonist clinically used for Alzheimer's disease (Parsons et al., 2007) and well-tolerated in children (Findling et al., 2007; Bouhadoun et al., 2021). Since memantine can potentially have pharmacological effects on targets other than NMDAR (Parsons et al., 2007; Moriguchi et al., 2018), we investigated whether memantine can potentially have an inhibitory effect on P212L in cultured neuron conditions. Multiplex imaging of R-CaMP2 and hK2 α was performed in response to 30 photostimulations at 20 Hz in the presence of 0, 1, 10, and 100 μM of memantine. R-CaMP2 peak amplitude was decreased in a memantine concentration-dependent manner, with the signal being reduced to about half at 10 μM and most of the responses being lost at 100 μM (0 μM : 2.1 ± 0.056 , $n = 22$; 1 μM : 1.9 ± 0.064 , $p = 0.56$, $n = 27$; 10 μM : 1.3 ± 0.17 , $p < 0.001$, $n = 23$; 100 μM : 0.26 ± 0.068 , $n = 22$, $p < 0.001$, compared to 0 μM , one-way ANOVA followed by Dunnett's test) (Figure 8B), suggesting inhibition of NMDAR. Accordingly, the responses of hK2 α P212L were also attenuated at 10 and 100 μM memantine (0 μM : 0.32 ± 0.030 , $n = 22$; 1 μM : 0.25 ± 0.032 , $p = 0.24$, $n = 27$; 10 μM : 0.13 ± 0.033 , $p < 0.001$, $n = 23$; 100 μM : 0.020 ± 0.0054 , $p < 0.001$, $n = 22$, compared to 0 μM , one-way ANOVA followed by Dunnett's test, compared with 0 μM) (Figure 8A). Similarly, WT hK2 α showed a memantine concentration-dependent suppression of R-CaMP2 and hK2 α responses (Figures 8C,D). These findings suggest that memantine may be a candidate agent for an interventional approach to suppress the accelerated Ca^{2+} /CaM-dependent activation of P212L.

Discussion

In this study, we identified the P212L *de novo* mutation in a patient with ID. Previous studies have examined the effect of P212L mutation on protein expression, threonine 286 phosphorylation, and cortical neuronal cell migration

during development, but the effects of this mutation on the CaMKII α at the molecular and cellular levels were not clarified. In this study, to examine Ca^{2+} /CaM-dependent activation, which is fundamental to CaMKII α function but had never been examined in P212L, we utilized our hK2 α probe to develop a FRET-based optical molecular phenotyping system. Conventionally, Ca^{2+} /CaM-dependent CaMKII activation has been performed by kinase assays measuring the incorporation of radiolabeled phosphate into substrates (De Koninck and Schulman, 1998). However, quantifying Ca^{2+} /CaM-dependent activation using substrate-based readout can be complicated by different Ca^{2+} /CaM-dependency between substrates (Coultrap et al., 2014) and kinase regulation mediated by Ca^{2+} /CaM-dependent autophosphorylation of threonine 286, threonine 305, and threonine 306 (Cook et al., 2021), making it critical for direct readout of kinase activation state *per se*. Since hK2 α probe reports activated conformation of the kinase (Fujii et al., 2013), it has the advantage of specifically detecting the activation state of the kinase without the need for the substrates, allowing for a more direct comparison of the mutations found in the kinase gene (Fujii and Bito, 2022). Thus, our FRET-based optical molecular phenotyping system provides a selective, sensitive, quantitative, and a scalable platform for the mutational analysis of the human CaMK2A gene. The platform will be applicable to other mutations in CAMK2A and CAMK2 isoforms related to various diseases (Iossifov et al., 2014; Küry et al., 2017; Akita et al., 2018; Chia et al., 2018; Brown et al., 2021; Proietti Onori and van Woerden, 2021; Mutoh et al., 2022) to reveal unappreciated molecular phenotypes in the future.

The present study clearly revealed that P212L mutation aberrantly facilitated Ca^{2+} /CaM-dependent activation. P212L is located in the kinase domain at a hydrophobic core formed with the regulatory domain, and *in silico* analysis predicted that P212L substitution destabilized the hydrophobic core and impaired the interaction between the kinase and the regulatory domains (Akita et al., 2018). Adding our findings, it could be suggested that Ca^{2+} /CaM can be more readily accessible or the regulatory domain can be more ready to release the kinase domain, which likely leads to a faster activation and a slower deactivation process in P212L.

High throughput FRET-based optical molecular phenotyping system revealed that aberrantly facilitated Ca^{2+} /CaM-dependent activation was observed not only in P212L-specific molecular phenotype, but rather it was more widespread among CAMK2A *de novo* mutations associated with ID. So far, mutations associated with ID have been found in the kinase and the regulatory domains of CaMKII α (Küry et al., 2017; Akita et al., 2018), while mutations found in schizophrenia patients were distributed in the kinase domain and the association domain (Brown et al., 2021). Since the kinase domain and the regulatory domain are involved in Ca^{2+} /CaM-dependent activation, and the association domain is involved in dodecameric to tetradecameric holoenzyme formation, which is crucial for the regulation of autophosphorylation




FIGURE 8 Memantine suppressed augmented activation of P212L. **(A)** Activation traces (left) and dose-response curve (right) of hK2α P212L in response to 30 photo-stimulations delivered at 20 Hz under 0, 1, 10, 100 μM memantine. $n = 22$ for 0 μM, 27 for 1 μM, 23 for 10 μM and 22 for 100 μM. *(Continued)*

FIGURE 8 (Continued)

*** $p < 0.001$, one-way ANOVA followed by Dunnett's test. **(B)** Activation traces (left) and dose-response curve (right) of R-CaMP2 in neurons co-expressed with hK2 α P212L in response to 30 photo-stimulations delivered at 20 Hz under 0, 1, 10, 100 μ M Memantine. $n = 22$ for 0 μ M, 27 for 1 μ M, 23 for 10 μ M and 22 for 100 μ M. *** $p < 0.001$, one-way ANOVA followed by Dunnett's test. **(C)** Activation traces (left) and dose-response curve (right) of hK2 α WT in response to 30 photo-stimulations delivered at 20 Hz under 0, 1, 10, 100 μ M memantine. $n = 22$ for 0 μ M, 22 for 1 μ M, 23 for 10 μ M and 23 for 100 μ M. * $p < 0.05$, *** $p < 0.001$, one-way ANOVA followed by Dunnett's test. **(D)** Activation traces (left) and dose-response curve (right) of R-CaMP2 in neurons co-expressed with hK2 α WT in response to 30 photo-stimulations delivered at 20 Hz under 0, 1, 10, 100 μ M Memantine. $n = 22$ for 0 μ M, 22 for 1 μ M, 23 for 10 μ M and 23 for 100 μ M. *** $p < 0.001$, one-way ANOVA followed by Dunnett's test.

of threonine 286 through inter-subunit reaction, it raises the possibility that distinct molecular phenotypes of CaMKII α can be underlying different disease phenotypes, and our data supports this hypothesis.

The mechanism of how the abnormal facilitation of Ca²⁺/CaM-dependent activation of P212L leads to the ID phenotype is currently unknown. However, in various animal models having CaMKII α mutants with altered Ca²⁺/CaM-dependent activation, activation kinetics and frequency tuning of CaMKII α have been shown to correlate with abnormalities in the regulation synaptic plasticity as well as learning and memory.

In CaMKII α T286A knock-in mice, the frequency dependence of CaMKII α activation and synaptic plasticity was tuned toward high-frequency input (Chang et al., 2017). The T286A knock-in mice had learning deficiency and required more repetition to form memory (Giese et al., 1998; Irvine et al., 2005). Transgenic mice constitutively expressing phosphor-mimicking mutant T286D had an altered frequency-tuning curve for synaptic plasticity that favored the induction of long-term depression at 5–10 Hz stimulation (Mayford et al., 1995). The mice showed impaired spatial memory (Bach et al., 1995) and abnormal properties of hippocampal place cells firing (Rotenberg et al., 1996), suggesting that abnormal plasticity tuning may induce altered network-level properties in the brain. Furthermore, in inducible T286D transgenic mice, in which transgene expression levels could be altered by changing Dox administration during development, high T286D expression suppressed hippocampal LTP, while low T286D expression promoted LTP (Mayford et al., 1996; Bejar et al., 2002). There were correlations between T286D expression and fear conditioning or water maze performance, consistent with our hypothesis that abnormal activation of CaMKII α drives the behavioral phenotypes. In mutants in which the inhibitory phosphorylation sites of CaMKII α , threonine 305, and threonine 306 were mutated with alanine, the dissociation of Ca²⁺/CaM was slower (Chang et al., 2019). In T305V/T306A mutant mice, although protein expression levels, abundant in the PSD, or threonine 286 autophosphorylation levels were comparable to the control, frequency tuning of long-term potentiation was tuned to lower frequency and flexibility in learning and the specificity of memory was reduced (Elgersma et al., 2002).

Based on these previous results and our results that P212L showed aberrantly enhanced Ca²⁺/CaM-dependent activation and frequency-response of CaMKII α , we speculate that P212L mutation would lead to altered frequency tuning of synaptic plasticity and induce deficiencies in learning and memory. However, facilitated Ca²⁺/CaM-dependent activation also possibly affects the level of Ca²⁺/CaM-stimulated phosphorylation of threonine 286, the level of inhibitory phosphorylation of threonine 305 and threonine 306, and binding to NMDAR. So, it is important to investigate these properties as well as to generate a knock-in mouse model of P212L in future studies.

Some of the mutants analyzed could have molecular phenotypes other than facilitated Ca²⁺/CaM-dependent activation. A112V mutant showed Ca²⁺/CaM-dependent activation similar to WT in a plate reader FRET assay but showed a significantly smaller response in living neurons. This suggests the possibility that molecular processes other than Ca²⁺/CaM-dependent activation could be disrupted in A112V, which remains to be elucidated. In E183V, although Ca²⁺/CaM-dependent modulation was significantly smaller compared to WT, consistent with the decreased catalytic activity of E183V (Stephenson et al., 2017), the baseline FRET ratio was unexpectedly elevated. A previous study had shown that CaMKII α introduced with E183V mutation had enhanced ubiquitination and reduced stability (Stephenson et al., 2017). Therefore, it may be possible that accelerated degradation may break down the donor and acceptor of FRET probe, or may prohibit sufficient maturation of fluorescent proteins (Liu et al., 2018), increasing the baseline FRET ratio. P235L showed no significant changes in our optical molecular phenotyping system, although multiple comparison made phenotypic detection difficult. It is necessary to clarify the molecular phenotype of these mutations by combinatorially examining other molecular properties of CaMKII α in future studies.

Our results suggest that WT is slightly more sensitive to memantine than P212L; however the underlying mechanism is currently not well-understood. Under conditions partially inhibited by memantine (1–10 μ M), the influx of Ca²⁺ is partially reduced rather than completely blocked (Figure 8) and forms a lower concentration of Ca²⁺/CaM. Under these conditions, P212L, which can be activated at lower Ca²⁺/CaM concentrations (Figure 3), is likely to be activated more than

WT. Furthermore, as the binding of activated CaMKII α to GluN2B further enhances the interaction with Ca²⁺/CaM and results in an autonomous state (Strack and Colbran, 1998; Bayer et al., 2001), these molecular processes may possibly amplify CaMKII α activation and lead to the differences in memantine sensitivity.

WT and P212L kinase subunits are considered to form hetero dodecamers in patients having heterozygous WT and P212L CAMK2A alleles, making it difficult to selectively inhibit P212L over WT pharmacologically. Since the dose-response curve of WT/P212L for memantine would be intermediate between the WT and the P212L, 1–10 μ M of memantine could potentially reduce the aberrant activation of CaMKII α in the WT/P212L to the same degree as in the WT under vehicle conditions. In future studies, the effectiveness of this approach needs to be assessed in knock-in model mice.

Data availability statement

The whole-exome sequencing datasets presented in this study can be found in online repositories. The name of the repository and accession number can be found at: DNA Data Bank of Japan (DDBJ) Japanese Genotype-phenotype Archive (JGA), <https://www.ddbj.nig.ac.jp/jga/index-e.html>, JGAS000522. Other datasets that support the findings are available from the corresponding authors, HF and HB, upon reasonable request.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of the Nagoya University Graduate School of Medicine. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. The animal study was reviewed and approved by the institutional review committees of the University of Tokyo Graduate School of Medicine.

Author contributions

HF, HK, ST-K, and HB conceived the study. HF performed plasmid construction, multiplex imaging, plate reader assays, statistical analysis, and wrote the manuscript. HK collected clinical data, assisted in data interpretation and manuscript preparation, and reviewed the manuscript. YK performed plasmid construction and plate reader assays. MK collected clinical data, assisted in data interpretation, and reviewed the manuscript. SH performed Sanger sequence. JN coordinated and supervised data collection and critically reviewed the manuscript for important intellectual content. All authors contributed to the article and approved the submitted version.

Funding

This work was supported in part by grants from Grant-in-Aid for Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) (JP19dm0207079 to HB), Brain Information Dynamics (BID) (JP17H06312 to HB), JSPSKAKENHI (JP17K13270 to HF, JP22H00432, and JP22H05160 to HB, and JP21H05091 to ST-K), Takeda Science Foundation (to HF and HB), Nakatani Foundation (to HB), Astellas Foundation for Research on Metabolic Disorders (to HF), Hitachi Global Foundation (to HB), and the Toray Science Foundation (ST-K).

Acknowledgments

We thank the following researchers for kindly sharing their reagents: A. Miyawaki and T. Nagai (Venus). We also thank the members of the HB laboratory for their support and discussion. We also thank the Tokai regional branch of the Initiative on Rare and Undiagnosed Diseases (TOKAI-IRUD). More importantly, we are grateful to the patient and their families for participating in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnmol.2022.970031/full#supplementary-material>

SUPPLEMENTARY FIGURE 1

R-CaMP2 Responses in Living Neurons co-Expressing hK2 α Mutants Associated With ID. (A–J) R-CaMP2 activation kinetics in response to 30 photo-stimulations delivered at 5 Hz (left) and 20 Hz (right) To aid comparison, response curve of R-CaMP2 co-expressed with hK2 α WT are overlaid (shaded blue traces) in each mutant data [red traces, (B–J)]. Mean \pm s.e.m. are shown. $n = 14$ for E183V and H282R, $n = 15$ for WT, E109D, and T286P, $n = 16$ for F98S, A112V, P212L, P212Q, and P235L.

SUPPLEMENTARY FIGURE 2

Comparison of hK2 α and R-CaMP2 responses. (A–D) Peak amplitude of hK2 α and R-CaMP2 responses in response to photo-stimulations delivered at 5 Hz (A,B) or 20 Hz (C,D). Each dot plots represent data from

each neuron and black bar represents mean. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. one-way ANOVA followed by Dunnett's test compared with WT. $n = 14$ for E183V and H282R, $n = 15$ for WT, E109D, and T286P, $n = 16$ for F98S, A112V, P212L, P212Q, and P235L.

References

- Akita, T., Aoto, K., Kato, M., Shiina, M., Mutoh, H., Nakashima, M., et al. (2018). *De novo* variants in CAMK2A and CAMK2B cause neurodevelopmental disorders. *Ann. Clin. Transl. Neurol.* 5, 280–296. doi: 10.1002/acn.3.528
- Bach, M. E., Hawkins, R. D., Osman, M., Kandel, E. R., and Mayford, M. (1995). Impairment of spatial but not contextual memory in CaMKII mutant mice with a selective loss of hippocampal LTP in the range of the theta frequency. *Cell* 81, 905–915. doi: 10.1016/0092-8674(95)90010-1
- Bayer, K. U., De Koninck, P., Leonard, A. S., Hell, J. W., and Schulman, H. (2001). Interaction with the NMDA receptor locks CaMKII in an active conformation. *Nature* 411, 801–805. doi: 10.1038/35081080
- Bayer, K. U., and Schulman, H. (2019). CaM kinase: still inspiring at 40. *Neuron* 103, 380–394. doi: 10.1016/j.neuron.2019.05.033
- Bejar, R., Yasuda, R., Krugers, H., Hood, K., and Mayford, M. (2002). Transgenic calmodulin-dependent protein kinase II activation: dose-dependent effects on synaptic plasticity, learning, and memory. *J. Neurosci.* 22, 5719–5726. doi: 10.1523/JNEUROSCI.22-13-05719.2002
- Bouhadoun, S., Poulin, C., Berrahmoune, S., and Myers, K. A. (2021). A retrospective analysis of memantine use in a pediatric neurology clinic. *Brain Dev.* 43, 997–1003. doi: 10.1016/j.braindev.2021.05.012
- Brown, C. N., Cook, S. G., Allen, H. F., Crosby, K. C., Singh, T., Coultrap, S. J., et al. (2021). Characterization of six CaMKII α variants found in patients with schizophrenia. *iScience*. 24, 103184. doi: 10.1016/j.isci.2021.103184
- Chang, J. Y., Nakahata, Y., Hayano, Y., and Yasuda, R. (2019). Mechanisms of Ca2+/calmodulin-dependent kinase II activation in single dendritic spines. *Nat. Commun.* 10, 2784. doi: 10.1038/s41467-019-10694-z
- Chang, J. Y., Parra-Bueno, P., Laviv, T., Szatmari, E. M., Lee, S. R., and Yasuda, R. (2017). CaMKII autophosphorylation is necessary for optimal integration of Ca2+ signals during LTP induction, but not maintenance. *Neuron*. 94, 800–808.e4. doi: 10.1016/j.neuron.2017.04.041
- Chia, P. H., Zhong, F. L., Niwa, S., Bonnard, C., Utami, K. H., Zeng, R., et al. (2018). A homozygous loss-of-function CAMK2A mutation causes growth delay, frequent seizures and severe intellectual disability. *Elife* 7, e32451. doi: 10.7554/eLife.32451
- Cook, S. G., Buonarati, O. R., Coultrap, S. J., and Bayer, K. U. (2021). CaMKII holoenzyme mechanisms that govern the LTP versus LTD decision. *Sci Adv.* 7, eabe2300. doi: 10.1126/sciadv.abe2300
- Coultrap, S. J., Freund, R. K., O'Leary, H., Sanderson, J. L., Roche, K. W., Dell'Acqua, M. L., et al. (2014). Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. *Cell Rep.* 6, 431–437. doi: 10.1016/j.celrep.2014.01.005
- De Koninck, P., and Schulman, H. (1998). Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. *Science* 279, 227–230. doi: 10.1126/science.279.5348.227
- Elgersma, Y., Fedorov, N. B., Ikonen, S., Choi, E. S., Elgersma, M., Carvalho, O. M., et al. (2002). Inhibitory autophosphorylation of CaMKII controls PSD association, plasticity, and learning. *Neuron* 36, 493–505. doi: 10.1016/S0896-6273(02)01007-3
- Findling, R. L., McNamara, N. K., Stansbrey, R. J., Maxhimer, R., Periclou, A., Mann, A., et al. (2007). A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. *J. Child Adolesc. Psychopharmacol.* 17, 19–33. doi: 10.1089/cap.2006.0044
- Fujii, H., and Bito, H. (2022). Deciphering Ca2+-controlled biochemical computation governing neural circuit dynamics via multiplex imaging. *Neurosci Res.* 179, 79–90. doi: 10.1016/j.neures.2022.04.004
- Fujii, H., Inoue, M., Okuno, H., Sano, Y., Takemoto-Kimura, S., Kitamura, K., et al. (2013). Nonlinear decoding and asymmetric representation of neuronal input information by CaMKII α and calcineurin. *Cell Rep.* 3, 978–987. doi: 10.1016/j.celrep.2013.03.033
- Giese, K. P., Fedorov, N. B., Filipkowski, R. K., and Silva, A. J. (1998). Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. *Science* 279, 870–873. doi: 10.1126/science.279.5352.870
- Hanson, P. I., Meyer, T., Stryer, L., and Schulman, H. (1994). Dual role of calmodulin in autophosphorylation of multifunctional CaM kinase may underlie decoding of calcium signals. *Neuron* 12, 943–956. doi: 10.1016/0896-6273(94)90306-9
- Hudmon, A., and Schulman, H. (2002). Neuronal CA2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. *Annu. Rev. Biochem.* 71, 473–510. doi: 10.1146/annurev.biochem.71.110601.135410
- Inoue, M., Takeuchi, A., Horigane, S., Ohkura, M., Gengyo-Ando, K., Fujii, H., et al. (2015). Rational design of a high-affinity, fast, red calcium indicator R-CaMP2. *Nat. Methods*. 12, 64–70. doi: 10.1038/nmeth.3185
- Iossifov, I., O'Roak, B. J., Sanders, S. J., Ronemus, M., Krumm, N., Levy, D., et al. (2014). The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 515, 216–221. doi: 10.1038/nature13908
- Irvine, E. E., Vernon, J., and Giese, K. P. (2005). AlphaCaMKII autophosphorylation contributes to rapid learning but is not necessary for memory. *Nat. Neurosci.* 8, 411–412. doi: 10.1038/nn1431
- Kanda, Y. (2013). Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant.* 48, 452–458. doi: 10.1038/bmt.2012.244
- Kennedy, M. B., Beale, H. C., Carlisle, H. J., and Washburn, L. R. (2005). Integration of biochemical signalling in spines. *Nat. Rev. Neurosci.* 6, 423–434. doi: 10.1038/nrn1685
- Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., et al. (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res.* 22, 568–576. doi: 10.1101/gr.129684.111
- Küry, S., van Woerden, G. M., Besnard, T., Proietti Onori, M., Latypova, X., Towne, M. C., et al. (2017). *De novo* mutations in protein kinase genes CAMK2A and CAMK2B cause intellectual disability. *Am. J. Hum. Genet.* 101, 768–788. doi: 10.1016/j.ajhg.2017.10.003
- Lee, S. J., Escobedo-Lozoya, Y., Szatmari, E. M., and Yasuda, R. (2009). Activation of CaMKII in single dendritic spines during long-term potentiation. *Nature* 458, 299–304. doi: 10.1038/nature07842
- Lisman, J., Malenka, R. C., Nicoll, R. A., and Malinow, R. (1997). Learning mechanisms: the case for CaMKII. *Science* 276, 2001–2002. doi: 10.1126/science.276.5321.2001
- Lisman, J., Yasuda, R., and Raghavachari, S. (2012). Mechanisms of CaMKII action in long-term potentiation. *Nat. Rev. Neurosci.* 13, 169–182. doi: 10.1038/nrn3192
- Liu, B., Mavrova, S. N., van den Berg, J., Kristensen, S. K., Mantovanelli, L., Veenhoff, L. M., et al. (2018). Influence of fluorescent protein maturation on FRET measurements in living cells. *ACS Sens.* 3, 1735–1742. doi: 10.1021/acssens.8b00473
- Matsuzaki, M., Honkura, N., Ellis-Davies, G. C., and Kasai, H. (2004). Structural basis of long-term potentiation in single dendritic spines. *Nature* 429, 761–766. doi: 10.1038/nature02617
- Mayford, M., Bach, M. E., Huang, Y. Y., Wang, L., Hawkins, R. D., and Kandel, E. R. (1996). Control of memory formation through regulated expression of a CaMKII transgene. *Science* 274, 1678–1683. doi: 10.1126/science.274.5293.1678
- Mayford, M., Wang, J., Kandel, E. R., and O'Dell, T. J. (1995). CaMKII regulates the frequency-response function of hippocampal synapses for the production of both LTD and LTP. *Cell* 81, 891–904. doi: 10.1016/0092-8674(95)90009-8
- Meyer, T., Hanson, P. I., Stryer, L., and Schulman, H. (1992). Calmodulin trapping by calcium-calmodulin-dependent protein kinase. *Science* 256, 1199–1202. doi: 10.1126/science.256.5060.1199

- Moriguchi, S., Ishizuka, T., Yabuki, Y., Shioda, N., Sasaki, Y., Tagashira, H., et al. (2018). Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy. *Mol. Psychiatry*. 23, 211–221. doi: 10.1038/mp.2016.187
- Mutoh, H., Aoto, K., Miyazaki, T., Fukuda, A., and Saito, H. (2022). Elucidation of pathological mechanism caused by human disease mutation in CaMKII β . *J. Neurosci. Res.* 100, 880–896. doi: 10.1002/jnr.25013
- Myers, J. B., Zaegel, V., Coultrap, S. J., Miller, A. P., Bayer, K. U., and Reichow, S. L. (2017). The CaMKII holoenzyme structure in activation-competent conformations. *Nat. Commun.* 8, 15742. doi: 10.1038/ncomms15742
- Nassal, D., Gratz, D., and Hund, T. J. (2020). Challenges and opportunities for therapeutic targeting of calmodulin kinase II in heart. *Front. Pharmacol.* 11, 35. doi: 10.3389/fphar.2020.00035
- Otmakhov, N., Tao-Cheng, J. H., Carpenter, S., Asrican, B., Dosemeci, A., Reese, T. S., et al. (2004). Persistent accumulation of calcium/calmodulin-dependent protein kinase II in dendritic spines after induction of NMDA receptor-dependent chemical long-term potentiation. *J. Neurosci.* 24, 9324–9331. doi: 10.1523/JNEUROSCI.2350-04.2004
- Parsons, C. G., Stöfler, A., and Danysz, W. (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. *Neuropharmacology* 53, 699–723. doi: 10.1016/j.neuropharm.2007.07.013
- Pellicena, P., and Schulman, H. (2014). CaMKII inhibitors: from research tools to therapeutic agents. *Front. Pharmacol.* 5, 21. doi: 10.3389/fphar.2014.00021
- Proietti Onori, M., and van Woerden, G. M. (2021). Role of calcium/calmodulin-dependent kinase 2 in neurodevelopmental disorders. *Brain Res. Bull.* 171, 209–220. doi: 10.1016/j.brainresbull.2021.03.014
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. *Genet. Med.* 17, 405–424. doi: 10.1038/gim.2015.30
- Rotenberg, A., Mayford, M., Hawkins, R. D., Kandel, E. R., and Muller, R. U. (1996). Mice expressing activated CaMKII lack low frequency LTP and do not form stable place cells in the CA1 region of the hippocampus. *Cell*. 87, 1351–1361. doi: 10.1016/S0092-8674(00)81829-2
- Shibata, A. C., Maebashi, H. K., Nakahata, Y., Nabekura, J., and Murakoshi, H. (2015). Development of a molecularly evolved, highly sensitive CaMKII FRET sensor with improved expression pattern. *PLoS ONE*. 10, e0121109. doi: 10.1371/journal.pone.0121109
- Stephenson, J. R., Wang, X., Perfit, T. L., Parrish, W. P., Shonesy, B. C., Marks, C. R., et al. (2017). A novel human CAMK2A mutation disrupts dendritic morphology and synaptic transmission, and causes ASD-related behaviors. *J. Neurosci.* 37, 2216–2233. doi: 10.1523/JNEUROSCI.2068-16.2017
- Strack, S., and Colbran, R. J. (1998). Autophosphorylation-dependent targeting of calcium/calmodulin-dependent protein kinase II by the NR2B subunit of the N-methyl-D-aspartate receptor. *J. Biol. Chem.* 273, 20689–20692. doi: 10.1074/jbc.273.33.20689
- Takao, K., Okamoto, K., Nakagawa, T., Neve, R. L., Nagai, T., Miyawaki, A., et al. (2005). Visualization of synaptic Ca²⁺/calmodulin-dependent protein kinase II activity in living neurons. *J. Neurosci.* 25, 3107–3112. doi: 10.1523/JNEUROSCI.0085-05.2005
- Takemoto-Kimura, S., Suzuki, K., Horigane, S. I., Kamijo, S., Inoue, M., Sakamoto, M., et al. (2017). Calmodulin kinases: essential regulators in health and disease. *J. Neurochem.* 141, 808–818. doi: 10.1111/jnc.14020
- Tanaka, H. (1987). *Tanaka-Binet Scale of Intelligence*. Tokyo: Taken Shuppan.
- Vissers, L. E., Gilissen, C., and Veltman, J. A. (2016). Genetic studies in intellectual disability and related disorders. *Nat. Rev. Genet.* 17, 9–18. doi: 10.1038/nrg3999
- Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 38, e164. doi: 10.1093/nar/gkq603
- Wing, L., Leekam, S. R., Libby, S. J., Gould, J., and Larcombe, M. (2002). The diagnostic interview for social and communication disorders: background, inter-rater reliability and clinical use. *J. Child Psychol. Psychiatry*. 43, 307–325. doi: 10.1111/1469-7610.00023
- Woolfrey, K. M., and Dell'Acqua, M. L. (2015). Coordination of protein phosphorylation and dephosphorylation in synaptic plasticity. *J. Biol. Chem.* 290, 28604–28612. doi: 10.1074/jbc.R115.657262
- Zhang, Y. P., Holbro, N., and Oertner, T. G. (2008). Optical induction of plasticity at single synapses reveals input-specific accumulation of alphaCaMKII. *Proc. Natl. Acad. Sci. USA*. 105, 12039–12044. doi: 10.1073/pnas.0802940105